Assessment of thickened endometrium in tamoxifen therapy
Tamoksifen kullanımında kalın endometriumun değerlendirilmesi

Engin Korkmazer¹, Neşe Solak², Vehbi Yavuz Tokgöz³

¹Giresun University Faculty of Medicine, Department of Gynecology and Obstetrics, Giresun, Turkey
²Giresun Maternity and Child Health Hospital, Clinic of Gynecology and Obstetrics, Giresun, Turkey
³Kızıltepe State Hospital, Clinic of Gynecology and Obstetrics, Mardin, Turkey

Abstract

Objective: Aim of this study was to evaluate role of hysteroscopy in thickened endometrium (>5 mm) associated with tamoxifen therapy.

Materials and Methods: We performed dilatation and curettage (D&C) and hysteroscopic biopsy to patients for evaluation of thickened endometrium in tamoxifen therapy. One hundred and nine asymptomatic patients with estrogen receptor positive breast cancer treated with tamoxifen 20 mg daily. We performed hysteroscopic biopsy or D&C to patients who have thickened endometrium at transvaginal sonography. We correlate pathology report results of D&C and hysteroscopic biopsy.

Results: Fifty-nine of 103 patients have thickened endometrium. Thirty-five of 59 patients diagnosed with D&C (19 inactive endometrium, 15 endometrial polypl, 1 endometrial hyperplasia). D&C couldn’t get material 24 of these patients. Hysteroscopic biopsy diagnosed endometrial polypl 11 (45.8%) of these patients.

Conclusion: We can state that D&C does not seem accurate enough for detection of intrauterin pathologies in thickened endometrium associated with tamoxifen therapy. We therefore believe it is reasonable to perform hysteroscopic biopsy in asymptomatic tamoxifen treated patients who have thickened endometrium. J Turk Soc Obstet Gynecol 2014;4:215-8

Key Words: Tamoxifen, hysteroscopy, dilatation and curettage, polyp

Conflict of Interest: The authors reported no conflict of interest related to this article.

Introduction

Tamoxifen is a nonsteroid antiestrogen, which has been used in chemoprevention of receptor-positive breast cancer(1). It has antiestrogenic effects in breast tissue and estrogenic effects on endometrium and myometrium. Long-term administration of tamoxifen makes several changes in the endocervix and endometrium (atrophy, polyposis, proliferation, vascular changes(2). The most serious effect on endometrium is increasing risk of developing endometrial carcinoma(3,4). Therefore, even if they are asymptomatic, these patients must be evaluated carefully. Transvaginal ultrasonography, sonohysterography, dilatation and curettage (D&C) and hysteroscopy have been used in the examination of tamoxifen-treated women with increased endometrial thickness (≥ 5 mm). Controversy exists regarding the most optimal method of screening. The value of Tv US in assessing endometrial thickness and endometrial characteristics improved with technological developments, however it hasn’t yet achieved sufficient sensitivity and specificity in patients with abnormal
endometrial thickness (5,6). Saline infusion sonohysterography is another method that has been proposed for the evaluation of such patients, but didn’t reached desired value(7). Although, D&C has been used as gold standard for many years, hysteroscopic evaluation and direct biopsy from the lesion has become superior to all approaches(8,9). In our study, asymptomatic patients with increased endometrial thickness in whom pathological specimen couldn’t be obtained during D&C were further evaluated by hysteroscopy and we present these hysteroscopic findings.

**Materials and Methods**

The study population consisted of 103 asymptomatic women attending Züleyse Ham maternity Hospital in Turkey. They were receiving 20 mg of tamoxifen daily for at least one year because of estrogen receptor positive breast cancer. Characteristics like age, gravida, Body mass index (BMI), duration of tamoxifen therapy and endometrial thickness were noted. Informed written consent was taken from all patients and details of the study were explained. After recording medical history and routine gynecological examination, endometrial thickness was measured by tvUS (5.0-MHz Aloka 500 system). The uterus was scanned sagitally in order to get anteroposterior measurements of endometrial axis view between the outermost edges of the line separating the hyperechogenic endometrium from the myometrium. The maximal width was recorded and endometrial thickness cut off ≥5 mm was set as criterion for significant abnormality. Fifty four patients had thickness in normal range and further evaluation was needless. In 59 patients (57.2%) endometrium was ≥5 mm and they attempted D&C. Pathology specimens were fixed in 10% formaldehyde, paraffin blocks prepared and after Hematoxylin and Eosin stain was performed. All histological samples were analysed by a single specialist gynaecological pathologist to ensure consistency of interpretation within trial. In endometrium thickened group (n=59), pathology specimen was obtained in 35 (59.3%; specimen-positive group) patients during D&C and in 24 (40.7%) women specimen couldn’t be obtained (specimen-negative group).

Further evaluation and biopsy was performed in specimen-negative group by hysteroscopy (Karl-Storz 3 mm telescope with 300 oblique lens, Karl Storz GmbH, Tuttlingen, Germany). Vaginoscopic hysteroscopy was performed and well tolerated by our patients and no anesthesia was used. The vagina and uterus was distended with 0.09% saline and endometrial cavity was visualized systematically beginning from tubal ostiums. From suspicious endometrial lesions biopsies were taken and all diagnosis were confirmed by biopsies. During D&C and hysteroscopy no complications were seen.

**Results**

One hundred and three tamoxifen receiving women for at least one year were enrolled in the study. Fifty nine of these women had endometrial thickening and the mean width was 11±5 mm and the mean age of women was 52±8.3 (43-74) and mean BMI was 27±4.7 kg/m². The demographic characteristics are presented on Table 1.

In specimen-positive group (n=35), most frequent histopathological finding was inactive endometrium (n=19, 54.2%) and second frequent diagnosis was endometrial polyp (n=15, 42.8%). Only one patient curettage revealed endometrial hyperplasia without atypia Table 2. In specimen-negative group (n=24), that attempted hysteroscopy, biopsy findings were inactive endometrium (n=13, 55.2%) and endometrial polyp (n=11, 45.8%) (Table 2). The group’s mean endometrial thickness was 8±3 mm. According to these results; in 40.6% of patients with endometrial thickening, during D&C specimen wasn’t obtained and they needed further evaluation with hysteroscopy.

**Discussion**

As adjuvant therapy, Tamoxifen reduces mortality rates among estrogen receptor positive breast cancer patients (10). Due to estrogenic effects on endometrium, tamoxifen increases risk for endometrial pathologies (3). Although, there is still controversy in follow up of asymptomatic tamoxifen receiving patients (11). In present study, endometrial cut off width was accepted as 5 mm, patients having values above ≥5 mm attempted invasive procedures (D&C, Hysteroscopic biopsy). In 27 (45.7%) of patients with endometrial thickening (n=59), endometrial pathologies were detected and it was consistent with literature (12). But on the other hand, more than half of the patients (n=32, 54.3%) had invasive procedures although they didn’t have an underlying endometrial pathology. In relation to proliferative effects of Tamoxifen on endometrium, Tamoxifen induces endometrial pathologies that can progress to endometrial cancer (2). In present study, 1 endometrial hyperplasia and no cases of cancer were detected. However, in high risk populations for endometrial cancer, such as patients undergoing Tamoxifen therapy, it is recommended to use biopsy and hysteroscopic evaluation in combination (13). Although it’s assumed that hysteroscopic examination in high risk patients for cancer, may increase the risk of dissemination of malignant cells into the peritoneal cavity; in recent meta-analyses no evidence was found to support an association between hysteroscopic examination and peritoneal cytology (14).

**Table 1.** Demographic characteristics of study group (n=59)

| Characteristic               | Value     |
|-----------------------------|-----------|
| Age                         | 52±8.3    |
| Gravida                     | 3±1.5     |
| Duration of Tamoxifen therapy | 3.2±1.3  |
| Body Mass Index             | 27±4.7    |
| Endometrial thickness (mm)  | 11±5      |
| Hypertension                | 25 (42.3%)|
| Diabetes                    | 26 (44%)  |
Quareshi et al, supported the association between prolonged tamoxifen therapy and endometrial pathology\(^{(15)}\). In our study, there was no correlation between duration of therapy and endometrial pathology (p=0.584). Dilatation and curettage was assumed as gold standard for assessment of endometrium, but in present study, during biopsies pathology specimen wasn’t obtained in 40.6% (n=24) of patients and D&C missed 18.6% (n=11) of endometrial pathologies. This highlights the difficulty of obtaining accurate histological data in D&C and this method alone would not provide sufficient information, especially in high-risk women. At this point, hysteroscopic evaluation and directed biopsy stands out in endometrial assessment among Tamoxifen users. Sensitivity and specificity of hysteroscopy is especially high for space occupying lesions of endometrium but its not good in some circumstances like hyperplasia\(^{(16)}\). Larger studies on this issue recommend hysteroscopic evaluation must be supported with biopsy\(^{(9)}\). Also in our study, there was underlying pathology in 45.8% of patients that hystopathologic specimen couldn’t be obtained during curettage, so it’s reasonable to support D&C with hysteroscopic evaluation and biopsy.

The main point against hysteroscopy as screening test in women receiving tamoxifen is difficulty in access and its limited acceptability from the patients. With development of modified approaches such as very thin atraumatic hystoscopes (2.9 mm), the rate of unsuccessful procedures is decreasing\(^{(17)}\). In our series, during vaginoscopic hysteroscopy, speculum is not used and the cervix is not clamped or dilated, general or even local anesthesia is not required. All of our hysteroscopic procedures were completed successfully and well tolerated by patients.

The main limitations of our study is small sample size and we couldn’t determine the real sensitivity and specificity of hysteroscopy, because it was only performed in specimen negative group.

In conclusion; endometrial thickness during tamoxifen therapy must be evaluated carefully because of increased endometrial cancer risk and in evaluation of this endometrium, with improvements in technology, it seems hysteroscopy and hysteroscopic biopsy will take place of conventional D&C.

**References**

1. Paschopoulos M, Kontostolis E, Lolis ED, Koliopoulos G, Alamanos Y, Paraskevaidis E. The use of transvaginal sonography and vaginoscopic hysteroscopy in women on tamoxifen. JSLS 2001;5:211-4.

2. Kedar R, Bourne T, Powles T, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-21.

---

**Table 2. Distribution of pathology results in patients with endometrial thickness ≥5 mm**

| Pathology                      | D&C ± Specimen (±) | Endometrial Polyp | Endometrial Hyperplasia | Inactive Endometrium |
|--------------------------------|--------------------|-------------------|--------------------------|----------------------|
| Endometrial Thickness ≥5 mm n:59| D&C ± Hysteroscopy (±) n:24 (40.6%) | Endometrial Polyp n:15 (42.8%) | Endometrial Hyperplasia n:1 (3%) | Inactive Endometrium n:19 (54.2%) |

---

Table 2. Distribution of pathology results in patients with endometrial thickness ≥5 mm
3. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrec H, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
4. Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, van Boven H, et al: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 2012;14:91.
5. Fung MF, Reid A, Faught W, Le T, Chenicier C, Verma S, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 2003;91:154-9.
6. Liedman R, Lindahl B, Andolf E, Willen R, Ingvar C, Ranstam J. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res 2000;20:4889-91.
7. Develioğlu OH, Omak M, Bilgin T, Esmer A, Tüfekçi M. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. Gynecol Oncol 2004;93:328-35.
8. Le Donne M, Lentini M, De Meo L, Benedetto V, Mesiti M. Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings. Eur J Gynaecol Oncol 2005;26:623-6.
9. Duffy S, Jackson TL, Lansdown M, Phillips K, Wells M, Pollard S, et al. ATAC Trials Group: The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. Hum Reprod 2005;20:294-301.
10. No authors listed. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trials Collaboration. Lancet 1992;339:1-5.
11. Gerber B, Krause A, Muler H, Reimer T, Kulz T, Makovitzky J, et al. Effects of adjuvant tamoxifene on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000;18:3464-70.
12. Le Donne M, Alibrandi A, Ciancimino L, Azzerbioni A, Chiofalo B, Triolo O. Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings. Oncology Letters 2013;5:1305-10.
13. Trimble CL, Method M, Leitao M, Lu K, Lofe O, Hampton M, et al. Management of endometrial precancers. Obstet Gynecol 2012;120:1160-75.
14. Yazbeck C, Dhainaut C, Batallan A, Benilla JL, Thoury A, Madelelat P. Diagnostic hysteroscopy and risk of peritoneal dissemination of tumor cells. Gynecol Obstet Fertil 2005;33:247-52.
15. Giorda G, Crivellari D, Veronesi A, Perin T, Campagnutta E, Carbone A, et al. Comparison of ultrasonography, hysteroscopy, and biopsy in the diagnosis of endometrial lesions in postmenopausal tamoxifen-treated patients. Acta Obstet Gynecol Scand 2002;81:975-80.
16. Giorda G, Scarabelli C, Franceschi S, Campagnutta E. Feasibility and pain control in outpatient hysteroscopy in postmenopausal women: a randomized trial. Acta Obstet Gynecol Scand 2000;79:593-7.
17. McIlwaine K, Readman E, Cameron M, Maher P. Outpatient hysteroscopy: factors influencing post-procedure acceptability in patients attending a tertiary referral centre. Aust N Z J Obstet Gynaecol. 2009;49:650-2.